These virological endpoints must be interpreted in the context of evaluating the clinical impact of treatment in the short, medium and long term, using serum ALT levels, changes in non-invasive markers of liver fibrosis, clinical events, and quality-of-life indices. The gene discussed is GPT; the disease is Hepatic fibrosis.